Document is current

Article History

Received: 23 November 2022

Accepted: 12 May 2023

First Online: 2 June 2023

Competing interests

: The authors declared the following competing financial interests. O.R. reported being a consultant for Rhenium. S.P-S. reported being a speaker for Exact Sciences, and Nanostring, A.S. reported being a consultant for Progenetics, H.G. reported receiving honoraria from Rhenium Oncotest. A.B-S. reported being a consultant for Oncotest, and Exact Sciences. L.S-G. reported being employed at Rhenium Oncotest. The authors declared the following competing nonfinancial interests. O.R. reported being a speaker for AstraZeneca, Boehringer Ingelheim, BMS, MSD, Novartis, Pfizer, Roche, Takeda and Teva, and being a consultant for NucleaiMD and Edocate. I.K. reported being a speaker and receiving travel support for Roche, Pfizer, and Medison. S.P-S. reported being a speaker for Roche, Novartis, Pfizer, and AstraZeneca, being a consultant for Roche, Novartis, Eli Lilly, Gilead, MSD, Pfizer and AstraZeneca, and receiving travel support from Roche and Pfizer. R.Y. reported being a speaker for Roche, Novartis, MSD, AstraZeneca, and Eli Lilly, and being a consultant for Roche, Pfizer, Novartis, Medison, AstraZeneca, Gilead, and Eli Lilly. A.S. reported being a speaker for Teva, Roche, Pfizer, Novartis, and Eli Lilly; being a consultant for Eli Lilly, Pfizer, Novartis, Roche, Gilead, MSD, and AstraZeneca, receiving travels/accommodation support from Neopharm, Celgene, Medison, and Roche, and receiving a grant from Novartis and Roche. E.G-Y. reported receiving honoraria from Roche, Novartis, Eli Lilly, Pfizer, MSD, and AstraZeneca. H.G. reported receiving honoraria from Roche, Novartis, Pfizer, and MSD, and being a consultant for Novartis, Pfizer, Eli Lilly, and Gilead. A.B-S. reported being a consultant for Pfizer and Can-Fite. Dr. Stemmer reported receiving research grant from Can-Fite, AstraZeneca, Bioline RX, BMS, Halozyme, Clovis Oncology, CTG Pharma, Exelexis, Geicam, Halozyme, Incyte, Lilly, Moderna, Teva pharmaceuticals, and Roche, and owning stocks and options in CTG Pharma, DocBoxMD, Tyrnovo, VYPE, Cytora, and CAN-FITE. The remaining authors declare no conflicts of interest.